CCCC Historical Income Statement
| CCCC Stock | USD 4.55 0.36 8.59% |
Historical analysis of C4 Therapeutics income statement accounts such as Net Interest Income of 6.9 M, Interest Income of 9 M or Depreciation And Amortization of 4.4 M can show how well C4 Therapeutics performed in making a profits. Evaluating C4 Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of C4 Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining C4 Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether C4 Therapeutics is a good buy for the upcoming year.
CCCC |
About CCCC Income Statement Analysis
C4 Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to C4 Therapeutics shareholders. The income statement also shows CCCC investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
C4 Therapeutics Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts C4 Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of C4 Therapeutics. It is also known as C4 Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from C4 Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into C4 Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 9 M, whereas Depreciation And Amortization is forecasted to decline to about 4.4 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 2.9M | 7.6M | 7.7M | 4.4M | Interest Income | 387K | 3.6M | 8.6M | 9.0M |
C4 Therapeutics income statement Correlations
Click cells to compare fundamentals
C4 Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
C4 Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 1.8M | (836K) | (1.8M) | 1.4M | 6.6M | 6.9M | |
| Interest Income | 1.8M | 393K | 387K | 3.6M | 8.6M | 9.0M | |
| Depreciation And Amortization | 1.6M | 2.8M | 2.9M | 7.6M | 7.7M | 4.4M | |
| Interest Expense | 2.2M | 1.2M | 2.1M | 2.2M | 1.4M | 1.7M | |
| Selling General Administrative | 8.8M | 15.2M | 33.3M | 42.8M | 42.1M | 27.4M | |
| Total Revenue | 21.4M | 33.2M | 45.8M | 31.1M | 20.8M | 31.5M | |
| Gross Profit | (26.3M) | (44.3M) | 42.9M | 23.5M | (97.0M) | (92.1M) | |
| Other Operating Expenses | 56.8M | 93.6M | 127.9M | 160.6M | 159.8M | 116.3M | |
| Operating Income | (35.5M) | (60.4M) | (82.1M) | (129.5M) | (139.0M) | (132.1M) | |
| Net Income From Continuing Ops | (34.1M) | (66.3M) | (83.9M) | (128.2M) | (134.9M) | (128.2M) | |
| Ebit | (35.5M) | (65.7M) | (81.7M) | (131.9M) | (129.8M) | (123.3M) | |
| Research Development | 48.1M | 78.4M | 94.7M | 117.8M | 117.7M | 89.0M | |
| Ebitda | (33.9M) | (62.9M) | (78.8M) | (124.3M) | (122.1M) | (116.0M) | |
| Total Operating Expenses | 56.8M | 93.6M | 127.9M | 160.6M | 159.8M | 116.3M | |
| Reconciled Depreciation | 1.6M | 1.6M | 1.5M | 1.7M | 2.0M | 1.8M | |
| Income Before Tax | (33.3M) | (67.0M) | (83.9M) | (128.2M) | (131.2M) | (124.7M) | |
| Total Other Income Expense Net | 2.2M | (6.5M) | (1.8M) | 1.4M | 7.8M | 8.2M | |
| Net Income Applicable To Common Shares | (42.6M) | (66.3M) | (83.9M) | (128.2M) | (115.4M) | (109.6M) | |
| Net Income | (34.1M) | (66.3M) | (86.0M) | (126.5M) | (132.5M) | (125.9M) | |
| Income Tax Expense | 804K | (626K) | 2.1M | (1.7M) | 1.3M | 1.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.